Rishi Bedi

Rishi Bedi is the CEO and Co-Founder of Y-Trap, a biotech company developing multifunctional fusion proteins for cancer immunotherapy.12 He has been leading Y-Trap since 2017, spearheading the development of their innovative cancer treatment approaches.2

Professional Background

Rishi's career spans several notable positions in the biotech and pharmaceutical industries:

• Consultant at Centivax (January 2021 - Present): He leads the company's computational science efforts, developing machine learning methods for antibody engineering.2

• Director of Machine Learning at Herophilus (2018 - 2020): He led the analysis of multi-omics and imaging datasets to identify deep phenotypes of neuropsychiatric diseases in cerebral organoids.2

• Antibody Engineering / Analysis at Distributed Bio Inc (2015 - 2018)1

• Research at Novartis (2015, less than a year)1

Education and Skills

Rishi Bedi earned his BS and MS in Computer Science from Stanford University.2 During his time at Stanford, he:

• Developed machine learning methods for structural biology in Ron Dror's research group
• Started a class on space policy

His expertise lies at the intersection of machine learning, immuno-oncology, and drug development.2

Languages

Rishi is proficient in Hindi and French.1

Current Work

At Y-Trap, Rishi's work has led to multiple internal programs advancing towards clinical development and a partnership with Merck KGaA, Darmstadt, Germany.2 His focus on developing multifunctional fusion proteins for cancer immunotherapy showcases his commitment to innovative approaches in biotechnology and healthcare.